Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02126943 · ClinicalTrials.gov registry record
OPsumit USers Registry
A clinical trial, sponsored by Actelion.
- Completed
- Registry status
- 2,686
- Enrollment target
NCT02126943 is a clinical trial that has completed, run by Actelion. The registered enrollment target is 2,686 participants.
The verdict
NCT02126943 has completed, sponsored by Actelion.
- COMPLETED
- Registry status
- 2,686 participants
- Enrollment target
Study Summary
Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
Interventions
- DRUG Opsumit (macitentan)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,686 participants |
| Start Date | 2014-04-30 |
| Est. Completion | 2020-04-24 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02126943
The ClinicalTrials.gov registry entry for NCT02126943 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2,686 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Actelion, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Opsumit (macitentan) is the first listed.
NCT02126943 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02126943 about?
NCT02126943 is a clinical study titled "OPsumit USers Registry". Prospective observational drug registry developed to characterize the safety profile (including primarily potential serious hepatic risks) and to describe clinical characteristics and outcomes of patients newly treated with Opsumit in the post-marketing setting.
What is the current status of trial NCT02126943?
This trial is currently completed. The enrollment target is 2,686 participants. The study started on 2014-04-30. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT02126943?
The interventions under investigation include: Opsumit (macitentan) (DRUG).
Who is sponsoring clinical trial NCT02126943?
This trial is sponsored by Actelion, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.